Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

Ji, Dong; Qin, Enqiang; Xu, Jing; Zhang, Dawei; Cheng, Gregory; Wang, Yudong; Lau, George

doi:10.1016/j.jhep.2020.03.044

Cited by 491 publications

(655 citation statements)

References 9 publications

Supporting

Mentioning

603

Contrasting

Unclassified

Order By: Relevance

“…2, However, Ji et al examined 202 patients with confirmed COVID-19, 37.6% of which with non-alcoholic fatty liver disease (NAFLD), and showed that elevated GGT levels portend a more severe course of the disease. 26 It remains unclear whether these laboratory test alterations are associated with a worse prognosis. In fact, the literature has shown different results.…”

Section: Covid -19 and Hepati C Inj Urymentioning

confidence: 99%

See 1 more Smart Citation

Review article: COVID‐19 and liver disease—what we know on 1st May 2020

Garrido

Liberal

Macedo

2020

Aliment Pharmacol Ther

167

187

View full text Add to dashboard Cite

SummaryBackgroundSevere acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the causative pathogen of coronavirus disease 2019 (COVID‐19), became a global threat to human health. Liver impairment has been frequently reported as a common manifestation, although its clinical significance is still unclear, particularly in patients with underlying chronic liver disease (CLD).AimsTo summarise the changes in liver function tests during SARS‐CoV‐2 infection and the impact of COVID‐19 in patients with underlying CLD.MethodsA literature review using online database PubMed was done using the search terms “SARS‐CoV‐2”, “COVID‐19”, “liver”, “cirrhosis” and “liver transplantation”.ResultsCOVID‐19 is frequently associated with different degrees of abnormal liver function tests, most notably transaminases, which are usually transitory and of mild degree. Available evidence suggests that liver injury may result from direct pathogenic effect by the virus, systemic inflammation or toxicity from commonly used drugs in this subset of patients. SARS‐CoV‐2 infection in children is associated with minimal or no increase in liver enzymes, thus the presence of abnormal liver function tests should trigger evaluation for underlying liver diseases. Although it seems that patients with CLD are not at greater risk for acquiring the infection, those with cirrhosis, hepatocellular carcinoma, non‐alcoholic fatty liver disease, autoimmune liver diseases or liver transplant may have a greater risk for severe COVID‐19.ConclusionsAbnormal liver function tests during the course of COVID‐19 are common, though clinically significant liver injury is rare. Further research is needed focusing on the effect of existing liver‐related comorbidities on treatment and outcome of COVID‐19.

show abstract

Section: Covid -19 and Hepati C Inj Urymentioning

confidence: 99%

“…7 Ji and colleagues showed that patients with NAFLD had a higher risk of progression to severe COVID-19 and longer viral shedding time. 26 Further research is needed to understand the impact of COVID-19 in NAFLD.…”

Section: Covid -19 and Cldmentioning

confidence: 99%

Review article: COVID‐19 and liver disease—what we know on 1st May 2020

Garrido

Liberal

Macedo

2020

Aliment Pharmacol Ther

167

187

View full text Add to dashboard Cite

show abstract

“…As previously reported, the expression of ACE2 is abundant also in the epithelia of intestine, and as there is a rich circulation of blood from the intestine to liver, the spread of the virus in the liver is expected. Reduced hepatic innate immune status could contribute to progression of COVID-19 [24][25][26].…”

Section: Pathway Analysismentioning

confidence: 99%

A protein interaction map identifies existing drugs targeting SARS-CoV-2

Cava

Bertoli

Castiglioni

2020

Preprint

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus (SARS-CoV-2), an emerging Betacoronavirus, is the causative agent of COVID-19. Angiotensin converting enzyme 2 (ACE2), being the main cell receptor of SARS-CoV-2, plays a role in the entry of the virus into the cell. Currently, there are no specific antiviral drugs for the treatment and neither preventive drugs such as vaccines. Results: We proposed a bioinformatics analysis in order to test in silico existing drugs as a fast way to identify an efficient therapy. We found differentially expressed genes in COVID-19 patients correlated with ACE-2 and we explored their direct relations with a network approach. Conclusions: In this network we integrated drug-gene interactions and we proposed several drugs with antiviral activity that, alone or in combination with other treatment options, could be considered as therapeutic approaches against COVID-19.

show abstract

“…These are risk factors for NAFLD and HCC [17]. Diabetes, hypertension, and obesity associated with NAFLD are also de- A preliminary report on NAFLD in patients with CO-VID-19 calls attention to an increased risk of disease progression [6.6% (5/126) vs. 44.7% (34/76) p < 0.0001], a higher probability of abnormal liver function on admission and at discharge [70% (53/76) vs. 11.1% (14/126) p < 0.0001], and a longer time for viral clearance (17.5 ± 5.2 days vs. 12.1 ± 4.4 days p < 0.0001), when compared with non-NAFLD individuals [18]. The authors state that NAFLD patients also had a higher risk of progression to severe COVID-19 and present an increased viral clearance time.…”

Section: The Impact Of Preexisting Liver Disease On Covid-19mentioning

confidence: 99%